VPM1002与Immuvac预防结核病的3期随机临床试验
两种疫苗安全性良好,但对微生物学确诊的全部结核病和肺结核无效;VPM1002对肺外结核显示一定效力,且结核菌素皮肤试验阳性者中两种疫苗对肺外结核均显示效力。
要点
- VPM1002对全部结核病和肺结核无效,但对肺外结核有显著效力。
- 两种疫苗在结核菌素皮肤试验阳性者中对肺外结核均显示效力。
- 两种疫苗安全性良好,约三分之一参与者出现轻微局部反应。
核心结论
- VPM1002和Immuvac均安全,但对微生物学确诊的全部结核病或肺结核未显示效力。
- VPM1002对肺外结核显示可观效力。
- 两种疫苗在结核菌素皮肤试验阳性参与者中对肺外结核显示效力。
研究设计与样本
- 3期随机临床试验(PreVenTB试验),在印度六个邦18个中心开展。
- 参与者按1:1:1随机分配接受皮内注射VPM1002、Immuvac或安慰剂,一个月后部分参与者接种第二剂。
- 主要结局为38个月随访期内确诊结核病(肺结核和肺外结核)的效力。
主要发现
- 符合方案分析中,VPM1002组65例(1.68%)、Immuvac组80例(2.09%)、安慰剂组82例(2.13%)发生结核病。
- VPM1002对全部结核病效力21.4%(95%CI -8.9%至43.2%),对肺结核19.5%(-14.6%至43.4%),对肺外结核50.4%(0.8%至75.2%)。
- Immuvac对肺外结核效力33.2%(-25.9%至64.5%)。
- 结核菌素皮肤试验阳性者中,VPM1002和Immuvac对肺外结核效力分别为64.9%(-2%至90.1%)和66.3%(1.9%至90.5%)。
- 两种疫苗均诱导结核分枝杆菌特异性多功能CD4+ T细胞。
关键数值与推荐
- VPM1002对肺外结核效力50.4%(95%CI 0.8%至75.2%)。
- Immuvac对肺外结核效力33.2%(95%CI -25.9%至64.5%)。
- 结核菌素皮肤试验阳性者中,VPM1002对肺外结核效力64.9%(95%CI -2%至90.1%),Immuvac为66.3%(95%CI 1.9%至90.5%)。
- 6-14岁参与者中VPM1002对全部结核病效力64.6%(95%CI 16.3%至85.1%),对肺结核62.1%(3.0%至85.2%),对肺外结核77.6%(-3.7%至95.2%)。
临床怎么用
- 两种疫苗安全性良好,可考虑用于进一步研究肺外结核预防。
- 在结核菌素皮肤试验阳性人群中,VPM1002和Immuvac可能对肺外结核提供保护。
- 目前证据不支持将VPM1002或Immuvac用于预防全部结核病或肺结核。
局限性
- VPM1002对全部结核病和肺结核的效力置信区间包含零,结果需谨慎解读。
- 6-14岁参与者的效力分析为事后分析,证据等级有限。
- 研究仅在印度开展,结果外推需考虑地区差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the safety and efficacy of VPM1002 and Immuvac in reducing the incidence of microbiologically confirmed tuberculosis (TB; pulmonary TB and extrapulmonary TB), development of latent TB infection, and immunogenicity. DESIGN: Phase 3 randomised clinical trial (PreVenTB trial). SETTING: 18 sites across six states of India. PARTICIPANTS: 12 717 healthy household contacts (aged ≥6 years) of patients with a smear positive TB test. INTERVENTIONS: Participants were randomly assigned in a 1:1:1 ratio (using block randomisation with variable sample size) to receive an intradermal injection of VPM1002, Immuvac, or placebo in both arms. After one month, a second dose was administered in one arm to 11 829 healthy participants. OUTCOME MEASURES: The primary outcome was efficacy against confirmed TB (pulmonary TB and extrapulmonary TB) over 38 months of follow-up. Secondary outcomes were development of latent TB infection, adverse and serious adverse events, efficacy in predefined age groups, and immunogenicity. Exploratory outcomes were efficacy when considering tuberculin skin test status, and post hoc analyses of efficacy in participants aged 6-14 and according to body mass index. RESULTS: 252 and 227 participants developed microbiologically confirmed TB in modified intention-to-treat and per protocol groups, respectively. The per protocol analysis showed 65 (1.68%), 80 (2.09%), and 82 (2.13%) participants developed TB in the VPM1002, Immuvac, and placebo groups, respectively. Of these, 12 (0.31%), 16 (0.42%), and 24 (0.62%) developed extrapulmonary TB in the VPM1002, Immuvac, and placebo groups, respectively. In the per protocol analysis, VPM1002 showed vaccine efficacy of 21.4% (95% confidence interval (CI) -8.9% to 43.2%), 19.5% (-14.6% to 43.4%), and 50.4% (0.8% to 75.2%) against all TB, pulmonary TB, and extrapulmonary TB, respectively. Immuvac showed vaccine efficacy of 33.2% (-25.9% to 64.5%) against extrapulmonary TB. VPM1002 and Immuvac showed vaccine efficacy of 64.9% (-2% to 90.1%) and 66.3% (1.9% to 90.5%) against extrapulmonary TB in participants with tuberculin skin test positivity. Both vaccines were well tolerated with mild local reactions in about a third of participants. VPM1002 and Immuvac induced Mycobacterium tuberculosis specific polyfunctional CD4+ T cells. Post hoc analyses showed vaccine efficacy of 64.6% (95% CI 16.3% to 85.1%) against all forms of TB, 62.1% (3.0% to 85.2%) against pulmonary TB, and 77.6% (-3.7% to 95.2%) against extrapulmonary TB in participants aged 6-14 years in the VPM1002 group. CONCLUSIONS: Both vaccines were safe but did not show any efficacy against all forms of microbiologically confirmed TB or pulmonary TB. VPM1002 showed considerable efficacy against extrapulmonary TB. Both vaccines showed efficacy against extrapulmonary TB in participants who had a positive tuberculin skin test. TRIAL REGISTRATION: Clinical Trials Registry India CTRI/2019/01/017026.
引用
- Singh M, Joshi S, Vohra V, et al. Efficacy and safety of VPM1002 and Immuvac in preventing tuberculosis: phase 3 randomised clinical trial (PreVenTB trial). BMJ. 2026. PMID: 41962942. doi:10.1136/bmj-2025-085716
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。